26.05.2016 08:00:00 CET

Increase of Nexstim Plc's share capital with subscriptions based on stock options 2010A, 2011A and 2013A


Company announcement, Helsinki, 26 May 2016, at 9:00 a.m.

Nexstim Plc (NXTMH: HEX, NXTMS: STO) is a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation. The company announces the subscription of 106,075 new shares in Nexstim Plc based on stock options 2010A, 2011A and 2013A. The corresponding increase in the company's share capital, i.e. EUR 1,060.75 to be credited to the company's invested unrestricted equity, will be registered in the Trade Register on or around 30 May 2016. Trading in the new shares registered at this time will commence on the Nasdaq First North Finland and Nasdaq First North Sweden on or around 1 June 2016. The right to dividends and other rights conferred by shares will come into effect when the increase in share capital has been registered in the Trade Register.

Nexstim Plc holds a total of 72.268 stock options under the stock option plans 2010A and 2013A. The remaining outstanding stock options 2010A and 2013A provide entitlement to subscribe for a maximum of 608.597 shares for EUR 0.01 per share. The share subscription period for stock option 2010A ends on 31 December 2016 and for stock option 2013A on 31 December 2020.
Nexstim Plc's share capital will be EUR 80,000 after the increase.

Martin Jamieson, CEO

Further information is available on the website www.nexstim.com or by contacting:

Martin Jamieson, CEO                                                                                     +447715163942

UB Securities Oy (Certified Adviser)                                                          +358 (0)9 2538 0246

Consilium Strategic Communications                                                       +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton                     nexstim@consilium-comms.com

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology as a diagnostic tool for brain surgery with its Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE-marked system based on the navigated transcranial magnetic stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the company has developed a device called Navigated Brain Therapy (NBTŪ) for use in the rehabilitation of stroke patients. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com


Nexstim Plc.